Dopamine News and Research

Latest Dopamine News and Research

UGA, Emory researchers awarded $1.9M grant to study role of regular exercise in attenuating drug abuse

A team of researchers at the University of Georgia and Emory University will receive $1.9 million over the next five years from the National Institutes of Health to study the neurobiological mechanisms for how regular aerobic exercise may prevent drug abuse relapse.

30 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Research finding sheds more light on the workings of lateral PFC

Whether it's for money, marbles or chalk, the brains of reward-driven people keep their game faces on, helping them win at every step of the way. Surprisingly, they win most often when there is no reward.

28 Apr 2010

New imaging protocol to visualize activity of brain's reward circuitry in individuals addicted to drugs

Researchers at the U.S. Department of Energy's Brookhaven National Laboratory have developed an imaging protocol that allows them to visualize the activity of the brain's reward circuitry in both normal individuals and those addicted to drugs. The technique could lead to better insight into why people take recreational drugs as well as help determine which treatment strategies might be most effective.

27 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

Medication and behaviour therapy help children with Attention Deficit Hyperactivity Disorder

Medication and behavioural interventions help children with Attention Deficit Hyperactivity Disorder (ADHD) better maintain attention and self control by normalising activity in the same brain systems, according to researchers at The University of Nottingham.

15 Apr 2010

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.

13 Apr 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick - pointing to a greater need for awareness and education around the condition and its treatment.

From Baxter International Inc. 8 Apr 2010

Non-conscious, learning systems of the brain simpler and evolutionarily older, study substantiates

A new study from the Swedish medical university Karolinska Institutet provides evidence that basic human learning systems use areas of the brain that also exist in the most primitive vertebrates, such as certain fish, reptiles and amphibians. The study involved an investigation into the limbic striatum, one of the evolutionarily oldest parts of the brain, and the ability to learn movements, consciously and unconsciously, through repetition.

7 Apr 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

5 Apr 2010

"Mouse model" study finds LRRK2 gene mutation may cause inherited Parkinson's disease

2 Apr 2010

Pramipexole ER uptake to be inhibited by availability of generic version

HealthLeaders-InterStudy and Fingertip Formulary find that the uptake of Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading dopamine agonist Mirapex that was approved earlier this month, will be inhibited by competition from generic pramipexole which became available earlier this year.

1 Apr 2010

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

Using new one-of-a-kind "mouse models" that promise to have a significant impact on future Parkinson's disease research, Mount Sinai School of Medicine researchers are among the first to discover how mutations in a gene called LRRK2 may cause inherited (or "familial") Parkinson's disease, the most common form of the disease. The study, published in The Journal of Neuroscience, is the first in vivo evidence that LRRK2 regulates dopamine transmission and controls motor performance, and that the mutation of LRRK2 eliminates the normal function of LRRK2, leading to Parkinson's disease.

1 Apr 2010

Unrestricted availability of food can trigger overconsumption and obesity

Some of the same brain mechanisms that fuel drug addiction in humans accompany the emergence of compulsive eating behaviors and the development of obesity in animals, according to research funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health.

29 Mar 2010

Addiction to high calorie fat rich food: likened to cocaine and heroin addiction

In a new research our worst fears are confirmed – fatty, fried and fattening foods are addictive. The addiction with these delicious ‘yummies’ may be as potent as that with cocaine or heroin. The study was conducted on experimental animals, rats in this case. When fed with fatty foods in great quantities these rats showed a compulsive need to eat.

29 Mar 2010

Study provides new clues to obesity epidemic

In a newly published study, scientists from The Scripps Research Institute have shown for the first time that the same molecular mechanisms that drive people into drug addiction are behind the compulsion to overeat, pushing people into obesity.

29 Mar 2010

Dopamine News and Research

Latest Dopamine News and Research

UGA, Emory researchers awarded $1.9M grant to study role of regular exercise in attenuating drug abuse

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Research finding sheds more light on the workings of lateral PFC

New imaging protocol to visualize activity of brain's reward circuitry in individuals addicted to drugs

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Medication and behaviour therapy help children with Attention Deficit Hyperactivity Disorder

Patients with RLS using rotigotine achieve sustained improvements

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Parents lack understanding of causes, signs and symptoms of dehydration in children

Non-conscious, learning systems of the brain simpler and evolutionarily older, study substantiates

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

"Mouse model" study finds LRRK2 gene mutation may cause inherited Parkinson's disease

Pramipexole ER uptake to be inhibited by availability of generic version

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

Unrestricted availability of food can trigger overconsumption and obesity

Addiction to high calorie fat rich food: likened to cocaine and heroin addiction

Study provides new clues to obesity epidemic

Quality, Patient Safety and Innovation Manager at Elsevier

How Bruker worked with the University of Manchester on mapping the dynamics of complex protein

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Dopamine News and Research

Latest Dopamine News and Research

Quality, Patient Safety and Innovation Manager at Elsevier

How Bruker worked with the University of Manchester on mapping the dynamics of complex protein

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Newsletters you may be interested in